ESC Professional Premium Access

Interrelation between baseline plaque characteristics and changes in coronary atherosclerosis with the PCSK9-inhibitor alirocumab: Insights from the PACMAN-AMI randomized trial

Congress Session

About the speaker

Doctor Konstantinos Koskinas

Bern University Hospital, Inselspital, Bern (Switzerland)
6 presentations
0 follower

2 more presentations in this session

State-of-the-art lecture in lipid lowering therapy and the atheroma .

Speaker: Professor S. Nicholls (Melbourne, AU)

Thumbnail

Longer-term safety of alirocumab with 24,610 patient-years of placebo-controlled observation: Further insights from the ODYSSEY OUTCOMES trial

Speaker: Doctor S. Goodman (Toronto, CA)

Thumbnail

Access the full session

Lipid-lowering therapy and the atheroma

Speakers: Doctor K. Koskinas, Professor S. Nicholls, Doctor S. Goodman
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk